ArticleMolecular medicine reports2020
lncRNA MALAT1 modulates cancer stem cell properties of liver cancer cells by regulating YAP1 expression via miR‑375 sponging.
Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- A meta-analysis of the clinicopathological significance of the lncRNA MALAT1 in human gastric cancer.Frontiers in oncology · 2023Pooled it
- Adaptation of Non-Invasive Cancer Cells to 3D Collagen I Microenvironment Induces Transcriptional Reprogramming Accompanied by a More Complex RNA Landscape.International journal of molecular sciences · 2026Article
- LINC01770 Is Associated with Stem-like Features and Aggressive Traits in Breast Cancer Cells Through a Putative miR-335-5p/OCT4 Axis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Pivotal role of long non-coding RNA in the development of new therapeutic approaches for plural mesothelioma.Discover oncology · 2026Review
- MALAT1 as a molecular driver of tumor progression, immune evasion, and resistance to therapy.Molecular cancer · 2025Review
- Non-coding RNAs and Hippo signaling in non-small cell lung cancer: emerging roles as biomarkers and therapeutic targets.Discover oncology · 2025Review
- Cancer stem cells in hepatocellular carcinoma: therapy resistance and emerging treatments.Frontiers in immunology · 2025Review
- Review
- Extracellular vesicles and cancer stem cells: a deadly duo in tumor progression.Oncology reviews · 2024Review
- Decoding oral cancer: insights from miRNA expression profiles and their regulatory targets.Frontiers in molecular biosciences · 2024Article
- Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.Molecular cancer · 2023Review
- Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment.Oncotarget · 2023Article
- Targeting Non-Coding RNAs for the Development of Novel Hepatocellular Carcinoma Therapeutic Approaches.Pharmaceutics · 2023Review
- Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma.World journal of gastroenterology · 2022Review
- The role of LINC01419 in regulating the cell stemness in lung adenocarcinoma through recruiting EZH2 and regulating FBP1 expression.Biology direct · 2022Article
- MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.Molecular medicine (Cambridge, Mass.) · 2022Review
- CircTUBGCP3 Contributes to the Malignant Progression of Rectal Cancer.Digestive diseases and sciences · 2022Article
- lncRNA MALAT1 promotes HCC metastasis through the peripheral vascular infiltration via miRNA-613: a primary study using contrast ultrasound.World journal of surgical oncology · 2022Article
- The role of YAP1 in liver cancer stem cells: proven and potential mechanisms.Biomarker research · 2022Review
- LncRNA RSU1P2-microRNA let-7a-Testis-Expressed Protein 10 axis modulates tumorigenesis and cancer stem cell-like properties in liver cancer.Bioengineered · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer stem cells (CSCs) are functionally defined by their ability to undergo self‑renewal, and may contribute to metastasis, recurrence and drug resistance in liver cancer. The long non‑coding RNA metastasis‑associated lung adenocarcinoma transcript 1 (MALAT1) has been implicated in tumor formation and metastasis of liver cancer. However, the exact mechanism by which MALAT1 modulates liver CSC features remains largely unknown. In the present study, the expression level of MALAT1 was elevated in cancer spheroids compared with the corresponding levels noted in parental liver cancer cells, whereas the suppression of MALAT1 resulted in markedly reduced sphere formation and decreased expression of stemness factors in liver cancer cells. Dual‑luciferase assay and RNA pull‑down assays further indicated an interaction between MALAT1 and microRNA (miR)‑375, and identified Yes‑associated protein 1 (YAP1) as a direct target of miR‑375 in liver cancer cells. In addition, YAP1 expression was correlated with MALAT1 in liver cancer. The reduced expression of YAP1 caused by knockdown of MALAT1 with MALAT1 small interfering RNA (si‑MALAT1) could be partially abolished by miR‑375 inhibition, suggesting that MALAT1 may regulate YAP1 expression by sponging miR‑375. Furthermore, YAP1 overexpression rescued the decrease in CSC features of liver cancer cells caused by si‑MALAT1, further supporting that MALAT1‑mediated YAP1 signaling was required for the stem‑like characteristics of liver CSCs. The present study revealed that MALAT1 may promote CSC properties of liver cancer cells by upregulating YAP1 expression via sponging miR‑375. The MALAT1/miR‑375/YAP1 axis may serve as a novel target for liver cancer therapy, particularly for the eradication of liver CSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.